DAY 5:
Significant difference was observed in the SARS COV-2 RNA error rate
between the molnupiravir group compared to the placebo group. (WMD:
4.91; 95% CI; [1.19, 8.63] p=0.01; I²=0%). (P-value for
subgroup differences = 0.05). (Fig 2A)
Overall: No significant difference observed in either
interventional groups, (WMD: 1.71; 95% CI; [-0.11, 3.53] p=0.07;
I²=49%).